These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 35529797)

  • 1. Picropodophyllin inhibits the growth of pemetrexed-resistant malignant pleural mesothelioma via microtubule inhibition and IGF-1R-, caspase-independent pathways.
    Sun R; Tanino R; Tong X; Haque EF; Amano Y; Isobe T; Tsubata Y
    Transl Lung Cancer Res; 2022 Apr; 11(4):543-559. PubMed ID: 35529797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dasatinib modulates sensitivity to pemetrexed in malignant pleural mesothelioma cell lines.
    Monica V; Lo Iacono M; Bracco E; Busso S; Di Blasio L; Primo L; Peracino B; Papotti M; Scagliotti G
    Oncotarget; 2016 Nov; 7(47):76577-76589. PubMed ID: 27391433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MiR-379/411 cluster regulates IL-18 and contributes to drug resistance in malignant pleural mesothelioma.
    Yamamoto K; Seike M; Takeuchi S; Soeno C; Miyanaga A; Noro R; Minegishi Y; Kubota K; Gemma A
    Oncol Rep; 2014 Dec; 32(6):2365-72. PubMed ID: 25231602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin.
    Giovannetti E; Zucali PA; Assaraf YG; Leon LG; Smid K; Alecci C; Giancola F; Destro A; Gianoncelli L; Lorenzi E; Roncalli M; Santoro A; Peters GJ
    Br J Cancer; 2011 Nov; 105(10):1542-53. PubMed ID: 21970874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Picropodophyllin inhibits proliferation and survival of diffuse large B-cell lymphoma cells.
    Strömberg T; Feng X; Delforoush M; Berglund M; Lin Y; Axelson M; Larsson O; Georgii-Hemming P; Lennartsson J; Enblad G
    Med Oncol; 2015 Jul; 32(7):188. PubMed ID: 26021470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of metallothionein-knockdown on cisplatin resistance in malignant pleural mesothelioma.
    Borchert S; Suckrau PM; Walter RFH; Wessolly M; Mairinger E; Steinborn J; Hegedus B; Hager T; Herold T; Eberhardt WEE; Wohlschlaeger J; Aigner C; Bankfalvi A; Schmid KW; Mairinger FD
    Sci Rep; 2020 Oct; 10(1):18677. PubMed ID: 33122816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Growth suppressive effect of pegylated arginase in malignant pleural mesothelioma xenografts.
    Lam SK; Li YY; Xu S; Leung LL; U KP; Zheng YF; Cheng PN; Ho JC
    Respir Res; 2017 May; 18(1):80. PubMed ID: 28464918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EGFR-targeted pemetrexed therapy of malignant pleural mesothelioma.
    Yang L; Fang H; Jiang J; Sha Y; Zhong Z; Meng F
    Drug Deliv Transl Res; 2022 Oct; 12(10):2527-2536. PubMed ID: 34802094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Indolyl-chalcone derivatives trigger apoptosis in cisplatin-resistant mesothelioma cells through aberrant tubulin polymerization and deregulation of microtubule-associated proteins.
    Steinlein S; Essmann F; Ghilardi AF; Horn H; Schüler J; Hausser A; Sun L; Ott G; Kalla C
    Front Oncol; 2023; 13():1190988. PubMed ID: 37305581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significance of osteopontin in the sensitivity of malignant pleural mesothelioma to pemetrexed.
    Takeuchi S; Seike M; Noro R; Soeno C; Sugano T; Zou F; Uesaka H; Nishijima N; Matsumoto M; Minegishi Y; Kubota K; Gemma A
    Int J Oncol; 2014 Jun; 44(6):1886-94. PubMed ID: 24714722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sorafenib inhibits ERK1/2 and MCL-1(L) phosphorylation levels resulting in caspase-independent cell death in malignant pleural mesothelioma.
    Katz SI; Zhou L; Chao G; Smith CD; Ferrara T; Wang W; Dicker DT; El-Deiry WS
    Cancer Biol Ther; 2009 Dec; 8(24):2406-16. PubMed ID: 20038816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 2-Deoxy-glucose Enhances the Effect of Cisplatin and Pemetrexed in Reducing Malignant Pleural Mesothelioma Cell Proliferation But Not Spheroid Growth.
    Gerogianni I; Pitaraki E; Jagirdar RM; Kouliou O; Giannakou L; Giannopoulos S; Papazoglou E; Hatzoglou C; Gourgoulianis KI; Zarogiannis SG
    Anticancer Res; 2019 Jul; 39(7):3809-3814. PubMed ID: 31262908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor Treating Fields (TTFields) downregulate the Fanconi Anemia-BRCA pathway and increase the efficacy of chemotherapy in malignant pleural mesothelioma preclinical models.
    Mumblat H; Martinez-Conde A; Braten O; Munster M; Dor-On E; Schneiderman RS; Porat Y; Voloshin T; Davidi S; Blatt R; Shteingauz A; Tempel-Brami C; Zeevi E; Lajterer C; Shmueli Y; Danilov S; Haber A; Giladi M; Weinberg U; Kinzel A; Palti Y
    Lung Cancer; 2021 Oct; 160():99-110. PubMed ID: 34482104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disturbance of the Warburg effect by dichloroacetate and niclosamide suppresses the growth of different sub-types of malignant pleural mesothelioma
    Lam SK; Yan S; Lam JS; Feng Y; Khan M; Chen C; Ko FC; Ho JC
    Front Pharmacol; 2022; 13():1020343. PubMed ID: 36304150
    [No Abstract]   [Full Text] [Related]  

  • 15. The therapeutic efficacy of anti vascular endothelial growth factor antibody, bevacizumab, and pemetrexed against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice.
    Li Q; Yano S; Ogino H; Wang W; Uehara H; Nishioka Y; Sone S
    Clin Cancer Res; 2007 Oct; 13(19):5918-25. PubMed ID: 17908988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autocrine CSF-1R signaling drives mesothelioma chemoresistance via AKT activation.
    Cioce M; Canino C; Goparaju C; Yang H; Carbone M; Pass HI
    Cell Death Dis; 2014 Apr; 5(4):e1167. PubMed ID: 24722292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The association of TP53 mutations with the resistance of colorectal carcinoma to the insulin-like growth factor-1 receptor inhibitor picropodophyllin.
    Wang Q; Wei F; Lv G; Li C; Liu T; Hadjipanayis CG; Zhang G; Hao C; Bellail AC
    BMC Cancer; 2013 Nov; 13():521. PubMed ID: 24182354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma.
    Jänne PA; Taffaro ML; Salgia R; Johnson BE
    Cancer Res; 2002 Sep; 62(18):5242-7. PubMed ID: 12234991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic activity of the c-Met and tubulin inhibitor tivantinib (ARQ197) with pemetrexed in mesothelioma cells.
    Leon LG; Gemelli M; Sciarrillo R; Avan A; Funel N; Giovannetti E
    Curr Drug Targets; 2014; 15(14):1331-40. PubMed ID: 25483224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterogeneity of neuroblastoma cell lines in insulin-like growth factor 1 receptor/Akt pathway-mediated cell proliferative responses.
    Qi L; Toyoda H; Shankar V; Sakurai N; Amano K; Kihira K; Iwasa T; Deguchi T; Hori H; Azuma E; Gabazza EC; Komada Y
    Cancer Sci; 2013 Sep; 104(9):1162-71. PubMed ID: 23710710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.